Medivisor to Provide Marketing for Mucotrol: Sees Growth Opportunity

HUNTINGTON STATION, NY--(Marketwire - June 13, 2007) - Medivisor, Inc. (PINKSHEETS: MVSR) today announced the extension of an existing contract with Cura Pharmaceutical Co., Inc. Under the new three-year contract, Medivisor will provide direct to physician marketing for Mucotrol™, used to treat various forms of oral ulcerations such as mucositis and stomatitis. This commission-based agreement with Cura allows for Medivisor to have the "exclusive" marketing rights for Mucotrol™. Furthermore, Cura and Medivisor are also in discussions for other innovative products which Cura intends to market in the USA territory.

"Medivisor is delighted to extend our relationship with Cura Pharmaceutical Co., Inc. With the exclusive rights to provide marketing to the healthcare industry and leveraging the e-Challenge program for Mucotrol™, we look forward to this mutually beneficial partnership. As a result, Medivisor will now be able to execute our growth strategy and continue to provide the Pharmaceutical Industry with targeted digital marketing," says Dino Luzzi, Chief Executive Officer of Medivisor, Inc.

About Mucotrol™

Mucotrol™ is an oral gel wafer that received 510-K approval as a device from the Food and Drug Administration in late November 2004, as a treatment for mouth sores related to chemotherapy. Mucotrol™ has a mechanical action indicated for the management and relief of pain by adhering to the mucosal surface of the mouth and soothing oral lesions of various origins including oral mucositis/stomatitis, which may be caused by chemotherapy or radiotherapy, irritation due to oral surgery and traumatic ulcers caused by braces or ill fitting dentures or diseases. Mucositis is a painful inflammation of the mucosa of the mouth. The National Cancer Institute estimates that approximately 300,000 cancer patients in the U.S. suffer from mucositis associated with cancer treatments.

About Cura Pharmaceutical Co., Inc.

Cura Pharmaceutical Co., Inc. is a privately held new pharmaceutical business that develops, distributes and sells innovative and generic pharmaceuticals. Cura feels that as a smaller specialized pharmaceutical company with an experienced executive team it can focus on disease states and/or therapies that, for various reasons, that have not yet been addressed. Cura will focus its corporate energy to provide products that are "medically necessary" yet not available in the U.S.A., contain ingredients that are difficult to develop or produce, are constantly in short supply, and that are suitable for only a small patient population. For more about Cura go to http://www.curapharma.com/index.htm.

About Medivisor, Inc.

Medivisor, Inc., a rapidly growing developer of next-generation focus driven marketing tools, was founded by Dino Luzzi, Chief Executive Officer, and incorporated in 2002. The company is based in Huntington Station, New York, and is dedicated to providing technologies that offer innovative and competitive advantages to the pharmaceutical industry and beyond. Medivisor, Inc. provides medical information to healthcare professionals, through its Web sites, using interactive, informational, video, and graphic presentations. It operates two Web sites, Statdose.com and Medivisor.com. Statdose.com communicates new products, services, and other medically relevant information and reaches its target audience of physicians/decision makers, including providers of continuing medical education courses; sponsors of medical conferences and seminars; and pharmaceutical companies, using an online marketing format known as e-detailing. Medivisor.com communicates with medical and pharmaceutical companies and now includes full-service integrated marketing solutions for all business needs. For more about Medivisor, Inc., go to http://www.medivisor.com.

SAFE HARBOR: Certain statements contained in this release may be deemed forward-looking statements, with respect to plans, projections, or future performance of the Company, the occurrence of which involves certain risks and uncertainties that could cause actual plans to differ materially from these statements. These risks and uncertainties include but are not limited to: market demand for the Company's tools, successful implementation of the Company's tools, competitive factors, the ability to manage the Company's growth, the ability to recruit and retrain additional software personnel, and the ability to develop new business lines.

326 Walt Whitman Road
Huntington Station, New York 11746
Phone: 631-549-7100
Fax: 631-549-7119

Contact Information: Contact: Dino Luzzi CEO Medivisor, Inc. 326 Walt Whitman Road Huntington Station, N.Y. 11746 Tel: 631.549.7100